Evofem Biosciences Reports Significant Convertible Debt and Derivative Financial Instruments in Q1 2023 Quarterly Report

Evofem Biosciences, Inc. (NASDAQ: EVFM), a leading women’s healthcare company, has disclosed vital information regarding its convertible debt and derivative financial instruments in its recently filed quarterly report for the first quarter of 2023. This article will provide an in-depth analysis of these financial disclosures based on the data provided in the report.

Convertible Debt

Convertible debt offers the potential to convert the liability into a fixed number of shares of the issuing company’s common stock. For the period ending March 31, 2023, Evofem reported several convertible debt positions. This includes convertible debt related to Baker Bros Notes, Adjuvant Notes, May 2022 Notes, December 2022 Notes, and February and March 2023 Notes.

Fair Value Disclosures

The fair value of the convertible debt reported was based on Level 3 inputs, which are unobservable inputs for which there is little or no market data available. This is an essential consideration for investors as it may indicate a higher degree of uncertainty and potential risk in valuing these securities.

Derivative Financial Instruments

Derivative financial instruments, such as warrants and options, provide a potential for significant upside if the underlying stock performs well. For the period ending March 31, 2023, Evofem reported various derivative financial instruments, including April and June 2022 Baker Warrants, May 2022 Public Offering Warrants, June 2022 Baker Warrants, December 2022 Warrants, February and March 2023 Warrants, and Rights.

These derivative financial instruments were also reported based on Level 3 inputs, indicating a higher degree of uncertainty and potential risk for investors.

Long-term Debt

In the same quarterly report, Evofem disclosed information on its long-term debt positions, including various notes due in the coming years. The long-term debt reported comprises Bakers First and Second Closing Notes, December 2022 Notes, February and March 2023 Notes, A50 Senior Subordinated Notes Due 2025 issued in January and March 2022, and Term Notes Total.

The fair values of these long-term debt positions were again based on Level 3 inputs, illustrating the uncertainty and risk associated with their valuation.


Overall, the recent quarterly report for Evofem Biosciences highlights the company’s significant convertible debt and derivative financial instruments positions. Given the reliance on Level 3 inputs for fair value estimations, potential investors should carefully consider the risks associated with these financial positions.

Additionally, it’s worth noting that the company’s long-term debt positions are also subject to similar uncertainty with Level 3 input valuation. As a result, investors should carefully assess the company’s financial health and the possible impact of these financial instruments on future performance.

It’s essential for investors to monitor the performance and developments of Evofem Biosciences, particularly in light of the Level 3 inputs and the potential risks associated with its financial positions. By staying informed, investors can make better-informed decisions about whether to invest in or divest from the company’s stock.

Note that we may hold securities mentioned in this article. All data is based on recent SEC filings. Even though we have implemented various manual and automatic fact-checking and data acquisition processes, some incorrect information may have slipped through (false positive). Let us know if you find any inconsistencies!